From Kellogg on Biotechnology: Thriving Through Integration
OVERVIEW
The pharmaceutical and biotechnology industries are intensely interested in the structure, function, production, and potential use of proteins as therapies to treat diseases. Much of the success within the biotech industry derives from the development of replicated human proteins to treat diseases that occur when the body makes too little of an important protein or when the presence of unusually large amounts of a protein generate a disease. A sample of approved biologicals is shown in Table 7.1. Many biopharmaceuticals target chronic diseases such as cancer and immune disorders, which typically require relatively large and repeated doses. As a result of the expected increase in high-volume biologic therapeutics on the market, many industry analysts have predicted significant shortages in the supply of biologics manufacturing capacity.
| Product | Company | Indication |
|---|---|---|
| Nonantibody Proteins | ||
| Actimmune | InterMune | Chronic granulomatous disease |
| Activase | Genentech | Acute myocardial infarction |
| Aranesp | Amgen | Anemia |
| AVINZA | Ligand Pharmaceuticals and Elan Corp. PLC | Pain |
| Avonex | Biogen | Relapsing multiple sclerosis |
| BeneFIX | Genetics Institute | Hemophilia B |
| Betaseron | Chiron/Shering AG | Relapsing, remitting multiple sclerosis |
| Cerzyme | Genzyme | Gaucher's disease |
| Crosseal | OMRIX | Adjunct to hemostasis |
| Eligard | Atrix Laboratories and Sanofi-Synthelabo | Prostate cancer |
| Epogen | Amgen | Anemia (Chronic Renal Failure) |
| Elitek | Sanofi-Synthelabo | Pediatric chemotherapy |
| FluMist | MedImmune | Vaccine, influenza virus |
| FortaFlex | Organogenesis, Inc., and Biomet, Inc. | Cuff repair |
| FORTEO | Eli Lilly | Osteoporosis |
| Hepsera | Gilead | Hepatitis B |
| Intron A | Shering-Plough | Hairy cell leukemia |
| INFUSE | Wyeth and Medtronic Sofamor Danek | Spinal surgery |
| Kineret | Amgen | Rheumatoid arthritis |
| Leukine | Immunex |
Products & Services
Topics of Interest
Dario Benavides, Lanier Coles, Gary Dulaney, Vanessa Rath, Carla Yarger OVERVIEW Once a new drug application (NDA) or biologic license application (BLA) is submitted to the U.S. Food and Drug...
Approaches to autoimmune antibody profiling using protein arrays Multiplexing technology holds the potential to become the standard for laboratory analyses. Craig S. Hixson and Steven R. Binder...
Chapter 3: Nanobiotechnology Applications and Commercialization Strategies Table 3.1: Specific Medical Applications for Nanobiotechnology Table 3.2: Commercialization Challenges Part II:...
If Biogen's Research Triangle Park (RTP), N.C. Large Scale Manufacturing facility proves anything, it's that plant construction needn't be a bottomless pit of delays, regulatory snags and cost...
Abnormal prion protein detection improved Researchers at the Serono Pharmaceutical Research Institute (Geneva) have developed a procedure that they believe will greatly improve the sensitivity of...
